Recorded Chinese product: 复方氨基酸注射液(15AA)复方氨基酸注射液(15AA)

This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。

Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。

生产企业Manufacturer

主要成分Active Ingredients

药物知识说明

L-丝氨酸(CHNO是一种在国家药监局注册认定的药品。该药品含有l-丙氨酸(chno、l-丝氨酸(chno、l-亮氨酸(chno-68a2369e等成分。

该药品关联的活性成分包括:l-丙氨酸(chno、l-丝氨酸(chno、l-亮氨酸(chno、l-异亮氨酸(chno、l-甲硫氨酸(chnos。这些成分信息来自国家药监局数据库。

该药品标注的生产企业为:安徽双鹤药业有限责任公司Chinese legal name: 安徽双鹤药业有限责任公司。

您可以探索含有相同成分的其他药品:l-丙氨酸(chno-0a761ac4成分药品。

本页面内容来自国家药监局数据库,MedicineGraph在此基础上提供关系图谱和知识导航。

Medicine Knowledge

This medicine (original name: 复方氨基酸注射液(15AA)) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).

Manufacturers recorded for this product: 安徽双鹤药业有限责任公司Chinese legal name: 安徽双鹤药业有限责任公司.

Explore other medicines containing the same ingredient: l-丙氨酸(chno productsProducts containing this recorded ingredient.

Source: MedicineGraph authoritative database. Relationships derived from registered product information.

这是什么What is this

  • 通用名/品名Recorded product name: 复方氨基酸注射液(15AA)Recorded Chinese product: 复方氨基酸注射液(15AA)
  • 规格Specification: 250ml∶20g(总氨基酸)Recorded Chinese specification: 250ml∶20g(总氨基酸)

本段仅展示注册/说明书已记录的身份属性,不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.

生产企业Manufacturer

  • 安徽双鹤药业有限责任公司Chinese legal name: 安徽双鹤药业有限责任公司

注册信息NMPA approval number

  • 批准文号NMPA approval number: 国药准字H19993069

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.

  • 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
  • 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.

本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.

English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.

NMPA approval number

国药准字H19993069

Manufacturer

Chinese legal name: 安徽双鹤药业有限责任公司 (domestically manufactured)

Indications

English translation unavailable. The original Chinese source label remains available below.

Dosage and administration

English translation unavailable. The original Chinese source label remains available below.

Adverse reactions

English translation unavailable. The original Chinese source label remains available below.

Contraindications

English translation unavailable. The original Chinese source label remains available below.

Precautions

English translation unavailable. The original Chinese source label remains available below.

Specification

English translation unavailable. The original Chinese source label remains available below.

中文说明书原文Original Chinese source label

批准文号

国药准字H19993069

生产企业

安徽双鹤药业有限责任公司(国产)

适应症

本品为氨基酸类药。能改善血浆蛋白水平和促进肝功能恢复。用于肝硬化,亚急性、慢性重症肝炎及肝昏迷的治疗,并可作为慢性肝炎的支持治疗。

用法用量

静脉滴注:一日250~500ml,用适量5%~10%葡萄糖注射液混合后缓慢滴注。滴速不宜超过每分钟20滴。

不良反应

输注过快可致心悸、恶心、呕吐等反应。

禁忌

严重酸中毒、充血性心力衰竭及肾功能衰竭患者慎用。

注意事项

1. 注射后剩余药液不能贮存再用。2. 本品遇冷能析出结晶,应微温溶解至37℃,澄明后方可使用。但药液如发生浑浊、沉淀时不可使用。3. 注射速度不宜过快。

规格

250ml∶20g(总氨基酸)

证据Evidence

  • 批准文号: 国药准字H19993069
  • rights: 本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据。National Medical Products Administration (China) medicine-registration data.

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.